Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492346 | 0.88 | ADORA1 (0.50) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL22492311 | 0.88 | ADORA1 (0.47) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL24209724 | 0.85 | ADORA1 (0.43) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL6440181 | 0.85 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL5720840 | 0.84 | NR1H2 (0.40) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL30090465 | 0.84 | NR1H2 (0.40) | NR1H2C5AR1USP2SMN1; SMN2F12 | |
| SCHEMBL30707227 | 0.82 | NR1H2 (0.39) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL29723403 | 0.81 | NR1H2 (0.38) | NR1H2ADORA1C5AR1USP2SMN1; SMN2 | |
| SCHEMBL24209760 | 0.81 | ADORA1 (0.45) | NR1H2ADORA1USP2SMN1; SMN2F12 | |
| SCHEMBL30707378 | 0.81 | NR1H2 (0.38) | NR1H2C5AR1USP2SMN1; SMN2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563346-A | Pyrrole [3,4-c ] pyrazole diamide derivatives and application thereof in antitumor drugs | 守恒(厦门)医疗科技有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113563346-A | Pyrrole [3,4-c ] pyrazole diamide derivatives and application thereof in antitumor drugs | 守恒(厦门)医疗科技有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| EP-3008068-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2020-12-30 | — | — | EP | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2794608-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| EP-2094081-B1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2012-07-11 | — | — | EP | disclosed |
| US-7855206-B2 | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855206-B2 | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855206-B2 | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| EP-2094081-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008060488-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060488-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NR1H2 2049/4885ADORA1 2830/4885C5AR1 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.